Mapping the effect of the apolipoprotein E genotype on 4-year atrophy rates in an Alzheimer disease-related brain network

Radiology

Volumn 271, Issue 1, 2014, Pages 211-219

  Hostage, Christopher A ^a   Choudhury, Kingshuk Roy ^a   Doraiswamy, P Murali ^a   Petrella, Jeffrey R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON 4; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

AGED; ALGORITHM; ALLELE; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BRAIN ATROPHY; BRAIN MAPPING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GRAY MATTER; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRIORITY JOURNAL; TEMPORAL CORTEX; ATROPHY; COMPUTER ASSISTED DIAGNOSIS; GENETICS; LONGITUDINAL STUDY; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ATROPHY; BIOLOGICAL MARKERS; FEMALE; GENOTYPE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS;

EID: 84896946952     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13131041     Document Type: Article

References (51)

1. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
2. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58(5):681-693. (Pubitemid 351778466)
3. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103(15):5644-5651.
4. Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. J Neurosci Res 2002;68(3):331-336. (Pubitemid 34462538)
5. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 1998;153(1):152-155. (Pubitemid 28452307)
6. Cedazo-Mínguez A, Hüttinger M, Cowburn RF. Beta-VLDL protects against A beta(1-42) and apoE toxicity in human SHSY5Y neuroblastoma cells. Neuroreport 2001;12(2):201-206. (Pubitemid 32114351)
7. Farlow MR. Alzheimer's disease: clinical implications of the apolipoprotein E genotype. Neurology 1997;48(5 Suppl 6):S30-S34. (Pubitemid 27232701)
8. West HL, Rebeck GW, Hyman BT. Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci Lett 1994;175(1-2):46-48.
9. Benjamin R, Leake A, McArthur FK, et al. Protective effect of apoE epsilon 2 in Alzheimer's disease. Lancet 1994;344(8920):473.
10. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69(3):757-761.
11. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56(3):303-308. (Pubitemid 29120227)
12. Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009;132(Pt 4):1067-1077.
13. Chiang GC, Insel PS, Tosun D, et al. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology 2010;75(22):1976-1981.
14. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15(4):869-877, xi-xii. (Pubitemid 43162384)
15. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008;27(4):685-691. (Pubitemid 351508080)
16. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74(3):201-209.
17. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995;273(16):1274-1278.
18. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE; Alzheimer's Disease Neuroimaging Initiative. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 2011;68(9):961-969.
19. ADNI MRI Protocols. http://adni.loni.usc.edu/methods/documents/mri- protocols/. Published 2008. Accessed April 12, 2012.
20. Ségonne F, Dale AM, Busa E, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004;22(3):1060-1075. (Pubitemid 38829195)
21. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33(3):341-355. (Pubitemid 34162530)
22. Sled JG, Zijdenbos AP, Evans AC. A non-parametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998;17(1):87-97. (Pubitemid 128742012)
23. Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging 2001;20(1):70-80. (Pubitemid 32293421)
24. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999;9(2):195-207. (Pubitemid 29369875)
25. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 2000;97(20):11050- 11055.
26. Han X, Jovicich J, Salat D, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006;32(1):180-194.
27. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61(4):1402-1418.
28. DeCarli C. Part IV. Neuroimaging in dementing disorders. Dis Mon 2000;46(10):706-724.
29. Thompson PM, Mega MS, Woods RP, et al. Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex 2001;11(1):1-16. (Pubitemid 32064172)
30. Thompson PM, Hayashi KM, de Zubicaray G, et al. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 2003;23(3):994-1005. (Pubitemid 36206191)
31. Knight WD, Kim LG, Douiri A, Frost C, Rossor MN, Fox NC. Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiol Aging 2011;32(10):1765-1773.
32. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009;63(2):178-188.
33. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009;62(1):42-52.
34. Sperling RA, Dickerson BC, Pihlajamaki M, et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 2010;12(1):27-43.
35. Putcha D, Brickhouse M, O'Keefe K, et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J Neurosci 2011;31(48):17680-17688.
36. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25(34):7709-7717. (Pubitemid 41208641)
37. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009;19(3):497-510.
38. Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008;71(10):743-749.
39. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010;6(2):67-77.
40. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC. Impact of APOE in mild cognitive impairment. Neurology 2004;63(10):1898-1901. (Pubitemid 39532387)
41. Pievani M, Rasser PE, Galluzzi S, et al. Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage 2009;45(4):1090-1098.
42. Liu Y, Paajanen T, Westman E, et al. Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J Alzheimers Dis 2010;21(3):947-966.
43. Reiman EM, Uecker A, Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 1998;44(2):288-291. (Pubitemid 28374124)
44. van de Pol LA, van der Flier WM, Korf ES, Fox NC, Barkhof F, Scheltens P. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007;69(15):1491-1497. (Pubitemid 47537855)
45. Morra JH, Tu Z, Apostolova LG, et al. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009;45(1 suppl):S3-S15.
46. Spampinato MV, Rumboldt Z, Hosker RJ, Mintzer JE; Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology 2011;258(3):843-852.
47. Tosun D, Schuff N, Shaw LM, Trojanowski JQ, Weiner MW; Alzheimer's Disease NeuroImaging Initiative. Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis 2011;26(Suppl 3):77-90.
48. Risacher SL, Shen L, West JD, et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2010;31(8):1401-1418.
49. Moffat SD, Szekely CA, Zonderman AB, Kabani NJ, Resnick SM. Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology 2000;55(1):134-136. (Pubitemid 30461016)
50. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7(2):180-184. (Pubitemid 24174658)
51. Shaw P, Lerch JP, Pruessner JC, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol 2007;6(6):494-500. (Pubitemid 46734757)